Bank of Montreal’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-35,586
| Closed | -$415K | – | 3664 |
|
|
2024
Q4 | $415K | Buy |
+35,586
| New | +$555K | ﹤0.01% | 2348 |
|
|
2024
Q2 | – | Sell |
-87,426
| Closed | -$2.46M | – | 4125 |
|
|
2024
Q1 | $2.46M | Buy |
+87,426
| New | +$2.43M | ﹤0.01% | 1525 |
|
|
2023
Q2 | – | Sell |
-7,714
| Closed | -$289K | – | 4197 |
|
|
2023
Q1 | $289K | Buy |
7,714
+1,270
| +20% | +$49.8K | ﹤0.01% | 2808 |
|
|
2022
Q4 | $321K | Buy |
+6,444
| New | +$306K | ﹤0.01% | 2872 |
|
|
2022
Q3 | – | Sell |
-68,437
| Closed | -$3.7K | – | 4315 |
|
|
2022
Q2 | $3.7K | Sell |
68,437
-54,728
| -44% | -$2.78M | ﹤0.01% | 1579 |
|
|
2022
Q1 | $9.08M | Buy |
123,165
+83,804
| +213% | +$7.1M | ﹤0.01% | 1199 |
|
|
2021
Q4 | $4.92M | Sell |
39,361
-3,062
| -7% | -$384K | ﹤0.01% | 1230 |
|
|
2021
Q3 | $5.85M | Buy |
42,423
+40,212
| +1,819% | +$6.09M | ﹤0.01% | 1557 |
|
|
2021
Q2 | $336K | Sell |
2,211
-606
| -22% | -$47.2K | ﹤0.01% | 3019 |
|
|
2021
Q1 | $206K | Sell |
2,817
-5,839
| -67% | -$392K | ﹤0.01% | 3105 |
|
|
2020
Q4 | $630K | Buy |
8,656
+5,964
| +222% | +$217K | ﹤0.01% | 2570 |
|
|
2020
Q3 | $56K | Sell |
2,692
-1,076
| -29% | -$22.4K | ﹤0.01% | 3379 |
|
|
2020
Q2 | $92K | Buy |
3,768
+3,509
| +1,355% | +$59.6K | ﹤0.01% | 3132 |
|
|
2020
Q1 | $3K | Sell |
259
-4,999
| -95% | -$67.3K | ﹤0.01% | 3786 |
|
|
2019
Q4 | $77K | Buy |
5,258
+1,300
| +33% | +$18.1K | ﹤0.01% | 3614 |
|
|
2019
Q3 | $52K | Buy |
3,958
+134
| +4% | +$2.14K | ﹤0.01% | 3605 |
|
|
2019
Q2 | $63K | Buy |
3,824
+3,069
| +406% | +$48.2K | ﹤0.01% | 3581 |
|
|
2019
Q1 | $13K | Buy |
755
+287
| +61% | +$4.28K | ﹤0.01% | 3795 |
|
|
2018
Q4 | $6K | Sell |
468
-561
| -55% | -$10.4K | ﹤0.01% | 4033 |
|
|
2018
Q3 | $30K | Sell |
1,029
-7
| -0.7% | -$204 | ﹤0.01% | 3578 |
|
|
2018
Q2 | $28K | Buy |
1,036
+736
| +245% | +$17.8K | ﹤0.01% | 3633 |
|
|
2018
Q1 | $6K | Sell |
300
-1,000
| -77% | -$24.6K | ﹤0.01% | 3890 |
|
|
2017
Q4 | $25K | Sell |
1,300
-4,984
| -79% | -$115K | ﹤0.01% | 3515 |
|
|
2017
Q3 | $155K | Sell |
6,284
-1,638
| -21% | -$30.9K | ﹤0.01% | 2771 |
|
|
2017
Q2 | $127K | Buy |
7,922
+7,222
| +1,032% | +$101K | ﹤0.01% | 2876 |
|
|
2017
Q1 | $10K | Sell |
700
-73
| -9% | -$980 | ﹤0.01% | 3551 |
|
|
2016
Q4 | $12K | Buy |
773
+73
| +10% | +$1.1K | ﹤0.01% | 3533 |
|
|
2016
Q3 | $12K | Buy |
+700
| New | +$13.5K | ﹤0.01% | 3509 |
|
Other funds holding NTLA
AIM
RP
NAMA
Bank of Montreal's NTLA Position: Q1 2025 in Review
Bank of Montreal sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 35,586 shares — an estimated $415K sold.
Bank of Montreal first reported a position in NTLA in Q3 2016 and held it in 28 quarters. The position peaked at $9.08M in Q1 2022. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.
- Bank of Montreal reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
- Bank of Montreal sold 35,586 Intellia Therapeutics shares in Q1 2025, an estimated $415K.
- Bank of Montreal first reported a position in Intellia Therapeutics in Q3 2016 and held it in 28 quarters.
- Bank of Montreal's Intellia Therapeutics position peaked at $9.08M in Q1 2022.
- 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.
Based on Bank of Montreal's 13F filing for Q1 2025, filed 13 May 2025.